Previous close | 20.83 |
Open | 20.93 |
Bid | 20.76 x 1300 |
Ask | 21.02 x 2200 |
Day's range | 20.67 - 21.30 |
52-week range | 12.32 - 45.43 |
Volume | |
Avg. volume | 1,238,250 |
Market cap | 877.221M |
Beta (5Y monthly) | 0.03 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.29 |
Earnings date | 26 Feb 2024 - 01 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 13 Dec 2012 |
1y target est | 99.50 |
With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s...
Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week Phase 3 trial expected approximately mid-year 2025.MRI safety data suggests simufilam is not associated with ARIA.$142.4 Million in cash and cash equivalents at September 30, 2023. AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.Top-line results for on-going, 76-week Phase 3 trial expected approximately mid-year 2025. AUSTIN, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate